-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KwmU/CUQb+/BXEeeB5Unn6oV7T70ZETFeHsPz/Z9YrVMsWyeuZwk9Ss7pJtlYqff UtZxlW55+7lPGHBYZ4cXLg== 0000950116-03-001579.txt : 20030212 0000950116-03-001579.hdr.sgml : 20030212 20030212130843 ACCESSION NUMBER: 0000950116-03-001579 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20030205 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20030212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMERICAN BIO MEDICA CORP CENTRAL INDEX KEY: 0000896747 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 141702188 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-28666 FILM NUMBER: 03553394 BUSINESS ADDRESS: STREET 1: 122 SMITH ROAD CITY: KINDERHOOK STATE: NY ZIP: 12106 BUSINESS PHONE: 8002271243 MAIL ADDRESS: STREET 1: 122 SMITH ROAD CITY: KINDERHOOK STATE: NY ZIP: 12106 8-K 1 eightk.txt EIGHTK.TXT SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 5, 2003 AMERICAN BIO MEDICA CORPORATION -------------------------------- (Exact Name of Registrant as Specified in its Charter)
New York 0-28666 14-1702188 - ------------------------------- ------------------------ ------------------------------------ (State or Other Jurisdiction of (Commission File Number) (IRS Employer Identification Number) Incorporation)
122 Smith Road, Kinderhook, NY 12106 --------------------------------------------------------- (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (800) 227-1243 ITEM 5. OTHER MATTERS On February 5, 2003, Daniel W. Kollin was appointed to the Registrant's Board of Directors. Mr. Kollin is a principal of BioMed Capital Group Ltd, a firm that offers strategic and business advisory services, based in Fairfield, New Jersey. Mr. Kollin was also appointed to the Registrant's Nominating Committee. ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL STATEMENTS AND EXHIBITS. (c) Exhibits. The following exhibits are filed with this report on Form 8-K: 99.1 American Bio Medica Corporation press release dated February 12, 2003. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AMERICAN BIO MEDICA CORPORATION (Registrant) Dated: February 12, 2003 By: /s/ Keith E. Palmer ------------------------------ Keith E. Palmer Chief Financial Officer Exhibit Index Exhibit No. Description Page No. - ----------- ----------- -------- 99.1 American Bio Medica Corporation press 5 release dated February 12, 2003. EX-99 3 exh99-1.txt EXH99-1.TXT EXHIBIT 99.1 FOR IMMEDIATE RELEASE: AMERICAN BIO MEDICA APPOINTS DANIEL W. KOLLIN TO ITS BOARD OF DIRECTORS KINDERHOOK, NY, February 12, 2003 - American Bio Medica Corporation (NASDAQ:ABMC) today announced that at a regular meeting held on February 5, 2003, the ABMC Board of Directors appointed Daniel W. Kollin to serve as a member of its Board of Directors. Kollin's appointment brings the total number of ABMC board members to seven. Mr. Kollin, 61, is a principal of BioMed Capital Group, Ltd., a firm that provides strategic and business advisory services. Kollin has over twenty years experience in investment banking, venture capital and corporate management, specializing in pharmaceutical, biotechnology and healthcare companies in North America and Europe. Kollin previously served as a Vice President of Prudential-Bache Capital Funding and Director of Corporate Finance and partner of Whale Securities Corp. Before his involvement in the financial services industry, Kollin held marketing, planning and development executive positions with Becton-Dickinson and Co. and Sandoz, Inc. Mr. Kollin currently serves on the Board of Directors of GenSci Regeneration Sciences Inc. (TORONTO:GNS.TO). He received his MBA from The Wharton School of the University of Pennsylvania. Gerald A. Moore, Chairman and Chief Executive Officer of ABMC commented, "We are proud to have a professional of Dan's caliber join our Board of Directors. He brings extensive strategic financial and management expertise in the fields of healthcare and biotechnology. We are confident he will be an important asset to our Board of Directors." Moore added, "The addition of Dan further enhances the independent structure of our board, bringing the number of independent directors to four." About American Bio Medica Corporation American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets inexpensive, accurate, immunoassay diagnostic test kits, including some of the world's most effective on-site drugs of abuse tests. The company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen(R), Rapid One(R), and Rapid Tec(TM) test for the presence or absence of drugs of abuse in urine, while OralStat6(R) tests for the presence or absence of drugs of abuse in saliva. ABMC was recently named among the 2002 Deloitte & Touche Technology Fast 500, a listing of the fastest-growing technology companies in North America. This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the transition period ended December 31, 2001, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares. -----END PRIVACY-ENHANCED MESSAGE-----